Abstract
Shift work causes misalignment between our internal clock and daily behavioural cycles and is associated with metabolic disorders and cancer. Here, we describe the relationship between shift work and prevalent asthma in >280,000 UK Biobank participants. Compared to day workers, ‘permanent’ night shift workers had a higher likelihood of moderate/severe asthma (odds ratio (OR) 1.36 (1.03-1.8)) and all asthma (OR 1.23 (1.03-1.46) after adjustment for known major confounders). The public health implications of this finding are far-reaching due to the high prevalence and co-occurrence of both asthma and shift work.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RJM is funded by Wellcome Trust Grant (107849/Z/15/Z) and Medical Research Council grant MR/P023576/1) DWR is a Wellcome Investigator Wellcome Trust (107849/Z/15/Z) and holds a Medical Research Council Programme grant (MR/P023576/1) CV was supported in part by the National Institutes of Health grant R01 DK105072. RS is supported by NIDDK R01DK102696 and R01DK107859 and MGH Research Scholar Fund. HSD is supported by NIDDK R01DK107859. FAJLS was supported in part by National Institutes of Health grants R01 DK102696 and R01 DK105072. SAS was supported by National Institutes of Health grants R01-HL-125893, R01-HL-142064 and R01-HL-140577, and by the Oregon Institute of Occupational Health Sciences via funds from the State of Oregon (ORS 656.630). SDK is supported by a NIHR Oxford Senior Fellowship and the NIHR Oxford Biomedical Research Centre. DAL Works in a Unit that is supported by the University of Bristol ((MC_UU_00011/6); She is a National Institute of Health Research Senior Investigator (NF-0616-10102). ASIL is a Wellcome Investigator Wellcome Trust (107849/Z/15/Z) JFB is funded by a MRC by a Medical research Council Grant (MR/L006499/1)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding RJM is funded by Wellcome Trust Grant (107849/Z/15/Z) and Medical Research Council grant MR/P023576/1)
DWR is a Wellcome Investigator Wellcome Trust (107849/Z/15/Z) and holds a Medical Research Council Programme grant (MR/P023576/1)
CV was supported in part by the National Institutes of Health grant R01 DK105072.
RS is supported by NIDDK R01DK102696 and R01DK107859 and MGH Research Scholar Fund. HSD is supported by NIDDK R01DK107859.
FAJLS was supported in part by National Institutes of Health grants R01 DK102696 and R01 DK105072.
SAS was supported by National Institutes of Health grants R01-HL-125893, R01-HL-142064 and R01-HL-140577, and by the Oregon Institute of Occupational Health Sciences via funds from the State of Oregon (ORS 656.630).
SDK is supported by a NIHR Oxford Senior Fellowship and the NIHR Oxford Biomedical Research Centre.
DAL Works in a Unit that is supported by the University of Bristol ((MC_UU_00011/6); She is a National Institute of Health Research Senior Investigator (NF-0616-10102).
ASIL is a Wellcome Investigator Wellcome Trust (107849/Z/15/Z)
JFB is funded by a MRC by a Medical research Council Grant (MR/L006499/1)
Competing Interests FAJLS has received lecture fees from Bayer HealthCare (2016), Sentara HealthCare (2017), Philips (2017), Vanda Pharmaceuticals (2017), and Pfizer Pharmaceuticals (2018).
DAL has received research support from Medtronic Ltd and Roche Diagnostics for research unrelated to that presented here.
MKR has received speaker fees and research support from Novo Nordisk and Roche Diabetes Care for research unrelated to that presented here.
Data Availability
Please contact corresponding author first author for access to data.
